BERGENBIO ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1504 NOK | -3.59% |
|
-7.96% | -45.90% |
Presenter SpeechMartin Olin (Executives)Good morning. My name is Martin Olin, I'm the CEO of B...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bergenbio ASA is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.
Calendar
2024-05-22
- Annual General Meeting
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
0.1504
NOK
Average target price
0.7667
NOK
Spread / Average Target
+409.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.90% | 53.23M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BGBIO Stock
- News BerGenBio ASA
- Transcript : BerGenBio ASA, Q4 2023 Earnings Call, Feb 14, 2024
